An Absolute Bioavailability Study of Evacetrapib in Healthy Subjects Using the Intravenous Tracer Method
Phase of Trial: Phase I
Latest Information Update: 04 Mar 2019
Price : $35 *
At a glance
- Drugs Evacetrapib (Primary) ; Evacetrapib (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 17 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Oct 2014 New trial record